Therapeutic Option for Hepatitis B and C: a French Cohort

Trial Profile

Therapeutic Option for Hepatitis B and C: a French Cohort

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir (Primary) ; Antivirals; Daclatasvir; Ribavirin; Simeprevir
  • Indications Hepatitis B; Hepatitis C
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms HEPATHER
  • Most Recent Events

    • 24 Oct 2017 Results (n=1808) assessing safety and efficacy of ledipasvir/sofosbuvir in HCV mono infected patients presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 24 Oct 2017 Results reporting the serious adverse events (SAE) which have been observed in the French cohort ANRS CO22 HEPATHER and analysing the current identified potential safety signals with direct acting antivirals presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 04 Oct 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Aug 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top